GlassScriptPhysician profile
Andrei M Dobrescu
NPI 1093949224
$1,281.81
in general payments reported to CMS, 2019-2025
26 companies · $233 in 2025
The $233 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29.08 · 2020: $12.45 · 2022: $345 · 2023: $393 · 2024: $270 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $875 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $874.76 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $178.71 | 2022-2024 | Enhertu |
| Karyopharm Therapeutics INC. | $137.44 | 2020-2023 | Xpovio |
| Epizyme, INC. | $125.00 | 2022 | |
| Amgen INC. | $90.21 | 2022 | |
| Pfizer INC. | $81.50 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $66.28 | 2023-2025 | |
| Gilead Sciences, INC. | $59.99 | 2024-2025 | Trodelvy |
| Abbvie INC. | $57.04 | 2023-2025 | Venclexta |
| Genzyme Corporation | $51.02 | 2023-2025 | |
| Astellas Pharma US INC | $50.43 | 2019-2023 | Xtandi, Padcev |
| Mirati Therapeutics, INC. | $43.46 | 2023-2024 | Krazati |
| Janssen Biotech, INC. | $41.00 | 2024 | Talvey, Tecvayli, Darzalex |
| Array Biopharma INC | $39.62 | 2024 | Xtandi, Inlyta, Talzenna |
| Exelixis INC. | $35.03 | 2023-2025 | Cabometyx |
| Merck Sharp & Dohme LLC | $32.10 | 2019-2023 | Keytruda |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $29.20 | 2023-2024 | Opdualag, Krazati |
| Boston Scientific Corporation | $23.42 | 2023 | Varithena Administration Pack |
| Astrazeneca Pharmaceuticals LP | $20.09 | 2024 | Enhertu |
| Dendreon Pharmaceuticals LLC | $19.76 | 2024 | Provenge |
| Ipsen Biopharmaceuticals, INC | $18.53 | 2025 | Onivyde |
| Blueprint Medicines Corporation | $18.43 | 2025 | Ayvakit |
| Deciphera Pharmaceuticals INC. | $17.09 | 2025 | Romvimza, Qinlock |
| Incyte Corporation | $16.92 | 2024 | Jakafi |
| Octapharma USA, INC. | $14.97 | 2024 | Octagam Immune Globulin (Human) |
| Emd Serono, INC. | $14.57 | 2023 | Tepmetko |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrei Dobrescu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.